Bone Mineral Density News and Research

RSS

Men with prostate cancer get stronger bones from playing football

Men with prostate cancer run the risk of brittle bones as a side-effect of their treatment. But one hour's football training a few times a week counters many of the negative effects of the treatment, according to University of Copenhagen scientists.

23 Nov 2015

Genvoya approved as complete regimen for HIV treatment

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

6 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

Low-weight, high-repetition resistance training increases bone density in adults

A new research study published in The Journal of Sports Medicine and Physical Fitness finds that low-weight, high-repetition resistance training increases bone mineral density in adults, challenging assumptions that heavy weight-training is required to build bone mineral density. Participants who completed the study experienced up to 8 percent bone mineral density increases in the legs, pelvis, arms and spine.

27 Oct 2015

Viking successfully completes safety, tolerability and pharmacokinetic study of VK5211 in elderly subjects

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the successful completion of a short-term safety, tolerability, and pharmacokinetic study of VK5211 in healthy elderly subjects. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed for the treatment of patients recovering from non-elective hip fracture surgery.

20 Oct 2015

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016.

19 Oct 2015

Neighbourhood exposure to fast food outlets associated with lower BMD and BMC in newborns

New research from the MRC Lifecourse Epidemiology Unit at the University of Southampton in the UK indicates that neighbourhood exposure to fast food outlets is potentially linked to poorer bone development in early childhood.

13 Oct 2015

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.

13 Oct 2015

$Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study$

Anti-osteoporotic therapy can decrease subsequent fracture risks by 40%: Study

Osteoporosis, a disease of progressive bone loss, affects 70 percent of the U.S. population older than age 50: one in two women--and one in five men. These individuals are at risk for fragility fractures, a break that results from a fall, or occurs in the absence of obvious trauma, and most commonly seen in the wrist, the upper arm, the hip, and the spine.

9 Oct 2015

$Bisphosphonate drugs linked to greater risk of atypical hip fractures$

Bisphosphonate drugs linked to greater risk of atypical hip fractures

The use of bisphosphonates, a group of drugs used to prevent hip breakages in women with osteoporosis, is associated with an increased risk of atypical fractures in this joint, understood as those that occur in less frequent locations.

22 Sep 2015

$Whole-genome sequencing identifies EN1 gene as determinant of bone mineral density, fracture$

Whole-genome sequencing identifies EN1 gene as determinant of bone mineral density, fracture

Using extensive genetic data compiled by the UK10K project, an international team of researchers led by Dr. Brent Richards of the Lady Davis Institute at the Jewish General Hospital has identified a genetic variant near the gene EN1 as having the strongest effect on bone mineral density (BMD) and fracture identified to date.

15 Sep 2015

Women with 'female athlete triad' at greater risk of bone stress injuries

Participation in sports by women and girls has increased from 310,000 individuals in 1971 to 3.37 million in 2010. At the same time, sports-related injuries among female athletes have skyrocketed.

2 Jul 2015

Researchers discover gene locations affecting wrist bones in children

Pediatric researchers have discovered gene locations affecting bone strength in wrist bones, the most common site for fractures in children. Children who have those genetic variants may be at higher-than-average risk of wrist fractures, and could especially benefit from activities and diets that promote bone strength.

30 Jun 2015

Scientists identify association between coronary heart disease and osteoporosis

University of Southampton scientists have discovered a link between coronary heart disease and osteoporosis, suggesting both conditions could have similar causes.

29 Jun 2015

Aeterna Zentaris selects Ergomed to manage Phase 3 clinical study of Macrilen

Aeterna Zentaris Inc. announced today that it has executed a definitive agreement with Ergomed PLC, pursuant to which Ergomed will manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD").

25 Jun 2015

Study suggests that dried plums may help support healthy bones

The International Symposium on Nutritional Aspects of Osteoporosis brings together the best scientific minds in bone health research and nutrition. Current research presented at the 2015 Ninth ISNAO has added to the increasing body of evidence that suggests dried plums (prunes) help to support healthy bones and may even promote attainment of peak bone mass.

18 Jun 2015

Recurrent major depression may increase osteoporosis risk in men

A recent study from the University of Eastern Finland in collaboration with Deakin University, Australia, shows that recurrent major depressive disorder (MDD) in men is associated with lower bone density. The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the person's weight and site of bone measurement.

12 Jun 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

Scientists find link between higher muscle mass and healthier bone development in children

Scientists at the University of Southampton have shown that higher muscle mass is strongly linked with healthier bone development in children.

15 Apr 2015

Aeterna Zentaris plans to conduct Macrilen Phase 3 clinical study for AGHD

Aeterna Zentaris Inc. today announced plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD"), as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization.

13 Apr 2015